Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis

References

• Abraham D, Hofbauer R, Schafer R, et al. (2000). Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 87:644–7
   PubMed Web of Science ®Google Scholar
• Buralli S, Dini FL, Ballo P, et al. (2010). Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol 105:853–6
   PubMed Web of Science ®Google Scholar
• Carmeliet P. (2005). Angiogenesis in life, disease and medicine. Nature 438:932–6
   PubMed Web of Science ®Google Scholar
• Cowie MR, Mosterd A, Wood DA, et al. (1997). The epidemiology of heart failure. Eur Heart J 18:208–25
   PubMed Web of Science ®Google Scholar
• Davies M, Hobbs F, Davis R, et al. (2001). Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 358:439–44
   PubMed Web of Science ®Google Scholar
• Diez J, Panizo A, Gil MJ, et al. (1996). Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis. Circulation 93:1026–32
   PubMed Web of Science ®Google Scholar
• Diez J, Querejeta R, Lopez B, et al. (2002). Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–7
   PubMed Web of Science ®Google Scholar
• Ellims AH, Taylor AJ, Mariani JA, et al. (2014). Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy. Circ Heart Fail 7:271–8
   PubMed Web of Science ®Google Scholar
• Franciosa JA, Wilen M, Ziesche S, et al. (1983). Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 51:831–6
   PubMed Web of Science ®Google Scholar
• Frantz S, Stork S, Michels K, et al. (2008). Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 10:388–95
   PubMed Web of Science ®Google Scholar
• George J, Patal S, Wexler D, et al. (2005). Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150:484–7
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. (2014). Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129:e28–e292
   Web of Science ®Google Scholar
• Grigorescu M. (2006). Noninvasive biochemical markers of liver fibrosis. J Gastrointest Liver Dis 15:149–59
   PubMedGoogle Scholar
• Hellawell JL, Margulies KB. (2012). Myocardial reverse remodeling. Cardiovasc Ther 30:172–81
   PubMed Web of Science ®Google Scholar
• Iraqi W, Rossignol P, Angioi M, et al. (2009). Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471–9
   PubMed Web of Science ®Google Scholar
• Izawa H, Murohara T, Nagata K, et al. (2005). Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112:2940–45
   PubMed Web of Science ®Google Scholar
• Izumiya Y, Shiojima I, Sato K, et al. (2006). Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47:887–93
   PubMed Web of Science ®Google Scholar
• Jaffe IZ, Newfell BG, Aronovitz M, et al. (2010). Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 120:3891–900
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Jr. Felker GM. (2013). Surfing the biomarker tsunami at JACC: heart failure. JACC Heart Fail 1:213–5
   PubMed Web of Science ®Google Scholar
• Kapur NK, Heffernan KS, Yunis AA, et al. (2011). Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion. Arterioscler Thromb Vasc Biol 31:443–50
   PubMed Web of Science ®Google Scholar
• Kaye DM, Khammy O, Mariani J, et al. (2013). Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. Eur J Heart Fail 15:292–8
   PubMed Web of Science ®Google Scholar
• Kitahara T, Takeishi Y, Arimoto T, et al. (2007). Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circ J 71:929–35
   PubMed Web of Science ®Google Scholar
• Klappacher G, Franzen P, Haab D, et al. (1995). Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75:913–18
   PubMed Web of Science ®Google Scholar
• Kodama Y, Kitta Y, Nakamura T, et al. (2006). Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 48:43–50
   PubMed Web of Science ®Google Scholar
• Koitabashi N, Danner T, Zaiman AL, et al. (2011). Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest 121:2301–12
   PubMed Web of Science ®Google Scholar
• Kupari M, Laine M, Turto H, et al. (2013). Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis. J Heart Valve Dis 22:166–76
   PubMed Web of Science ®Google Scholar
• Ky B, French B, Ruparel K, et al. (2011). The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 58:386–94
   PubMed Web of Science ®Google Scholar
• Leask A. (2010). Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106:1675–80
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. (2006). Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005
   PubMed Web of Science ®Google Scholar
• Lip GY, Chung I. (2005). Vascular endothelial growth factor and angiogenesis in heart failure. J Card Fail 11:285–7
   PubMed Web of Science ®Google Scholar
• Lopez B, Gonzalez A, Diez J. (2010). Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121:1645–54
   PubMed Web of Science ®Google Scholar
• Luttun A, Tjwa M, Moons L, et al. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831–40
   PubMed Web of Science ®Google Scholar
• Melkko J, Hellevik T, Risteli L, et al. (1994). Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179:405–12
   PubMed Web of Science ®Google Scholar
• Nagamatsu T, Fujii T, Kusumi M, et al. (2004). Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145:4838–45
   PubMed Web of Science ®Google Scholar
• Nakamura T, Funayama H, Kubo N, et al. (2009). Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 131:186–91
   PubMed Web of Science ®Google Scholar
• Onoue K, Uemura S, Takeda Y, et al. (2009). Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104:1478–83
   PubMed Web of Science ®Google Scholar
• Parenti A, Brogelli L, Filippi S, et al. (2002). Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res 55:201–12
   PubMed Web of Science ®Google Scholar
• Pilarczyk K, Sattler KJ, Galili O, et al. (2008). Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis 196:333–40
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–21
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–17
   PubMed Web of Science ®Google Scholar
• Pruthi D, McCurley A, Aronovitz M, et al. (2014). Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol 34:355–64
   PubMed Web of Science ®Google Scholar
• Querejeta R, Lopez B, Gonzalez A, et al. (2004). Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110:1263–8
   PubMed Web of Science ®Google Scholar
• Rahimi N, Golde TE, Meyer RD. (2009). Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res 69:2607–14
   PubMed Web of Science ®Google Scholar
• Risteli J, Elomaa I, Niemi S, et al. (1993). Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635–640
   PubMed Web of Science ®Google Scholar
• Smedsrod B, Melkko J, Risteli L, et al. (1990). Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345–50
   PubMed Web of Science ®Google Scholar
• Tang WH, Girod JP, Lee MJ, et al. (2003). Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108:2964–6
   PubMed Web of Science ®Google Scholar
• Udelson JE, Feldman AM, Greenberg B, et al. (2010). Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 3:347–53
   PubMed Web of Science ®Google Scholar
• Urena P, De Vernejoul MC. (1999). Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141–56
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Rigolin GM, Fucili A, et al. (2004). CD34 + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 110:1209–12
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–52
   PubMed Web of Science ®Google Scholar
• Yano K, Liaw PC, Mullington JM, et al. (2006). Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 203:1447–58
   PubMed Web of Science ®Google Scholar
• Zannad F. (2014). What is measured by cardiac fibrosis biomarkers and imaging? Circ Heart Fail 7:239–42.
   PubMed Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, et al. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700–706
   PubMed Web of Science ®Google Scholar
• Zannad F, McMurray JJ, Krum H, et al. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21
   PubMed Web of Science ®Google Scholar